The tweet was deleted by the author.
But we saved everything 🙂.
Greenwich LifeSciences, Inc. has announced the acceptance of its abstract and associated poster for publication at the upcoming 2026 ASCO Annual Meeting.
This development underscores the company's ongoing research efforts in oncology and its engagement with the global scientific community. The acceptance marks another milestone for Greenwich LifeSciences as it seeks to advance its clinical pipeline and gain further recognition within the industry.
Greenwich LifeSciences previously moved to secure new patent claims following statistically significant immune response data from its FLAMINGO-01 study, according to a recent disclosure. The company also announced a strategic update on its financing approach as it navigated current market conditions. These developments reflect continued efforts to support its clinical and operational initiatives.